We studied a new method of treatment of amyotrophic lateral sclerosis with autologous mesenchymal stem cells. Autologous mesenchymal stem cells were injected intravenously (intact cells) or via lumbar puncture (cells committed to neuronal differentiation). Evaluation of the results of cell therapy after 12-month follow-up revealed slowing down of the disease progression in 10 patients in comparison with the control group consisting of 15 patients. The cell therapy was safe for the patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10517-015-3017-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Functionalized Periosteum-Derived Microsphere-Hydrogel with Sequential Release of E7 Short Peptide/miR217 for Large Bone Defect Repairing.
Biomater Res
January 2025
Department of Orthopedics, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou 310000, China.
Large bone defects are still a persistent challenge in orthopedics. The availability limitations and associated complications of autologous and allogeneic bone have prompted an increasing reliance on tissue engineering and regenerative medicine. In this study, we developed an injectable scaffold combining an acellular extracellular periosteal matrix hydrogel with poly(d,l-lactate--glycol-acetate) microspheres loaded with the E7 peptide and miR217 (miR217/E7@MP-GEL).
View Article and Find Full Text PDF"Combined synergistic effects of concentrated growth factors and adipose-derived mesenchymal stem cells on regeneration of induced mandibular defects in rabbits".
Cytotherapy
December 2024
Department of Oral and Maxillofacial Surgery, School and Hospital of Stomatology, Hebei Technology Innovation Center of Oral Health, Hebei Medical University & Hebei Key Laboratory of Stomatology & Hebei Clinical Research Center for Oral Diseases, Shijiazhuang, 050017, China. Electronic address:
Objective: This study aimed to evaluate the potential of combining allogeneic adipose-derived mesenchymal stem cells (ADSCs) with autologous concentrated growth factors (CGF) to enhance the repair of mandibular defects in rabbits.
Methods: Rabbit ADSCs were characterized using flow cytometry, identifying CD73, CD90, and CD105 as surface markers, while Alizarin Red Staining confirmed osteogenic differentiation, showing substantial mineralized deposits by day 21. A total of 24 New Zealand white rabbits were divided into four groups: BLANK (control group), CGF, ADSCs, and ADSCs/CGF.
Forty Years of the Use of Cells for Cartilage Regeneration: The Research Side.
Pharmaceutics
December 2024
Laboratorio RAMSES, IRCCS Istituto Ortopedico Rizzoli, Via di Barbiano, 1/10, 40136 Bologna, Italy.
The treatment of articular cartilage damage has always represented a problem of considerable practical interest for orthopedics. Over the years, many surgical techniques have been proposed to induce the growth of repairing tissue and limit degeneration. In 1994, the turning point occurred: implanted autologous cells paved the way for a new treatment option based more on regeneration than repair.
View Article and Find Full Text PDFElevated IL-6 Expression in Autologous Adipose-Derived Stem Cells Regulates RANKL Mediated Inflammation in Osteoarthritis.
Cells
December 2024
Orthopedic Surgery, Inha University Hospital, Incheon 22332, Republic of Korea.
Interleukin-6 (IL-6) expression in mesenchymal stem cells (MSCs) has been shown to play a pivotal role in modulating cartilage regeneration and immune responses, particularly in the context of diseases that involve both degenerative processes and inflammation, such as osteoarthritis (OA). However, the precise mechanism through which IL-6 and other immune-regulatory factors influence the therapeutic efficacy of autologous adipose-derived stem cells (ASCs) transplantation in OA treatment remains to be fully elucidated. This study aims to investigate the relationship between IL-6 expression in autologous ASCs isolated from OA patients and their impact on immune modulation, particularly focusing on the regulation of Receptor Activator of Nuclear factor Kappa-Β Ligand (RANKL), a key mediator of immune-driven cartilage degradation in OA.
View Article and Find Full Text PDFMesenchymal stem cell therapy as a game-changer in liver diseases: review of current clinical trials.
Stem Cell Res Ther
January 2025
School of Medical Laboratory Science and Biotechnology, College of Medical Science and Technology, Taipei Medical University, 10F., Teaching & Research Building, Shuang-Ho Campus, No. 301, Yuantong Rd., Zhonghe Dist., Taipei, 235, Taiwan.
Chronic liver diseases, including cirrhosis and liver failure, remain formidable challenges due to their complex progression and limited therapeutic options. Mesenchymal stem cell (MSC) therapy has emerged as a game-changing approach, leveraging its potent immunomodulatory, anti-fibrotic, and regenerative capabilities, along with the ability to transdifferentiate into hepatocytes. This review delves into the latest advances in MSC-based treatments for chronic and end-stage liver diseases, as highlighted in current clinical trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!